Safety and efficacy of PD-1/PD-L1 immune checkpoint inhibitors in patients with pre-treated advanced stage malignant mesothelioma: a systematic review and meta-analysis

Safety and efficacy of PD-1/PD-L1 immune checkpoint inhibitors in patients with pre-treated advanced stage malignant mesothelioma: a systematic review and meta-analysis

Abstract Background Malignant mesothelioma is an aggressive cancer with poor prognosis. Programmed cell death protein-1 (PD-1) and its ligand 1 (PD-L1) immune checkpoint inhibitors (ICIs) have recently presented as a viable option in some first line but primarily as a second-line treatment of advanc...

Full description

Saved in:
Bibliographic Details
Main Authors: Amjad Zafar, Asma Abdul Rashid, Abdul Moeed, Muhammad Junaid Tahir, Ahmad Jamal Khan, Oadi N. Shrateh, Ali Ahmed
Format: Article
Language:English
Published: BMC 2024-11-01
Series:BMC Cancer
Subjects:
PD-1
PD-L1
Immune checkpoint inhibitors
Malignant mesothelioma
Online Access:https://doi.org/10.1186/s12885-024-13127-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items